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Abstract 14 
Chemoenzymatic strategies for the preparation of enantiopure β-hydroxytriazoles were designed. These and 15 
other related compounds are particularly relevant because of their antitubercular bioactivities and as β-16 
adrenergic receptor blockers. The ability of Rhodotorula mucilaginosa LSL to stereoselectively reduce 17 
prochiral ketones coupled to copper(I)-catalyzed azide-alkyne cycloaddition was exploited. The reactions 18 
were performed in aqueous medium and at room temperature. R. mucilaginosa LSL offered the advantage of 19 
internal redox cofactor recycling. Notably, the biocatalyst was compatible with all the chemicals required 20 
namely sodium azide, copper sulfate and alkynes and showed a broad substrate scope reducing small-bulky 21 
and bulky-bulky ketones stereoselectively. Considering this, two one-pot processes were assessed to 22 
synthesize enantiopure (R)-β-hydroxytriazoles. A one-pot, three-step sequential transformation allowed 23 
obtaining enantiopure products up to 65% yield starting from α-chloro arylketones. On the other hand, with α-24 
bromo arylketones, a one-pot cascade process furnished the same products in ca 80% isolated yield. 25 
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1. Introduction 1 
The combination of sustainable tools with efficient processes is continuously searched [1,2]. Particularly, one-2 
pot procedures minimize time, number of unit operations and costs of complex molecule synthesis. On the 3 
other hand, biocatalysts have gained place as promising tools in organic chemistry. A good example is the 4 
industrial synthesis of atorvastatin using a ketoreductase (KRED) and halohydrin dehalogenase (HHdH) in its 5 
synthetic route [3] Some biocatalysts have been tailored by protein engineering and designed for the synthesis 6 
of bioactive compounds [4,5].  7 
The asymmetric reduction of prochiral ketones is a good strategy to obtain enantiopure sec-alcohols, 8 
which can be used as building blocks for the synthesis of chiral pharmaceutical intermediates and fine 9 
chemicals. For this purpose, bioreductions mediated by ketoreductases (KRED) are widely used. 10 
There is a huge number of KRED described in literature that shows high stereoselectivity with a 11 
broad substrate scope [6] although most of them are limited to ketones bearing small-bulky 12 
substituents [7]. So far, only a few biocatalysts having the ability of reducing bulky-bulky ketones 13 
have been reported [8–11]. Nevertheless, the screening of new KRED possessing the ability of 14 
accommodating bulky substrates is still necessary for the expansion of the enzymatic toolbox. 15 
Azole compounds have been extensively studied as potential targets for drug discovery since they 16 
possess a broad range of biological properties, including antimicrobial, antiviral, antiepileptic, anti -17 
HIV [12]. In particular, 1,2,3-triazoles are active against tuberculosis [13–15]. Besides, β-18 
hydroxytriazole derivatives, specifically the R enantiomers, have been reported as potential β-19 
adrenergic receptor blockers [16,17].  20 
One of the most practical and reliable chemical methods to synthesize 1H-1,2,3-triazoles is the 21 
copper(I)-catalyzed azide-alkyne cycloaddition (CuAAC) under mild conditions via click chemistry 22 
[18]. Interesting examples for the preparation of enantiopure β-hydroxytriazoles derivatives by 23 
chemoenzymatic approaches can be surveyed in the literature, being ADHs the most employed 24 
enzymes in these multi-step procedures. In all these strategies, the stereocenter was defined before the 25 
CuAAC reaction [19–24]. In a recent report, a bioreduction of a β-ketotriazole was performed by a 26 
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strain of Penicillium citrinum affording the corresponding (S)-β-hydroxytriazole in high enantiomeric 1 
excess (ee) values [25]. 2 
Previously, we reported a novel wild type biocatalyst, Rhodotorula mucilaginosa LSL, isolated from a  soil  3 
sample of a landfarming site, capable of carrying out the stereoselective reduction of a series of arylketones 4 
[26]. In the present work, we took advantage of the robustness and broad substrate scope of R. mucilaginosa 5 
LSL to design chemoenzymatic processes with the aim of preparing (R)-β-hydroxytriazoles.  6 
 7 
2. Results and Discussion 8 
In a first approach, we synthesized (R)-β-hydroxytriazoles (7b-10b) with excellent ee values in a 9 
three-step sequential procedure starting from the commercially available 2-halo-1-phenylethanones 10 
(1a-4a). Thus, these compounds were treated with sodium azide and then the α-azidoketones (2 mM) 11 
were stereoselectively reduced to (R)-2-azido-1-arylethanols (5b and 6b) by whole cells of wild-type 12 
R. mucilaginosa LSL. The biocatalyst was used either as resting or lyophilized cells in phosphate 13 
buffer (30 mL, pH 6.5) and sucrose (1.2 g) at room temperature, without the addition of external 14 
redox cofactors, showing exquisite stereoselectivity, as previously reported [26]. Then, the purified 15 
azidoarylethanols (R)-5b and (R)-6b were subjected to CuAAC with either phenylacetylene or 16 
propargyl alcohol catalyzed by in situ formed Cu(I) [Cu(II)/ascorbate system] in a mixture of water-17 
dimethylsulfoxide (DMSO) at room temperature (Figure 1). In every case, the products were 18 
recovered in ca 40% final isolated yield (see Table S3, SI). 19 
Alternatively, we assessed the bioreduction of the β-ketotriazoles 7a-10a assuming that these bulky-bulky 20 
ketones could be accepted as substrates for the KRED of R. mucilaginosa LSL. A complete conversion to the 21 
corresponding (R)-β-hydroxytriazoles in 24 h was achieved and the stereoselectivity was excellent with ee 22 
values higher than 98% (Figure 2).  Taking into account the instability of the β-hydroxyazides [27] and based 23 
on these results, we decided to invert the last two steps of the synthetic route. Following this methodology, the 24 
overall yield increased reaching 60% of the isolated products (see Table S3, SI). In this manner, it was 25 
demonstrated that R. mucilaginosa LSL accepts α-azidoketones 5a-6a (small-bulky substrates) and β-26 
ketotriazoles 7a-10a (bulky-bulky substrates) (table 1) with the same stereopreference (R).  27 
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Encouraged by these results and in order to improve the yields of the (R)-β-hydroxytriazoles, we 1 
designed one-pot strategies. On the one hand, by starting from α-chloroketones, a one-pot, three-step 2 
sequential procedure was developed. In the first step, both compounds 5a and 6a were obtained by 3 
azidation of α-chloroacetophenones. Immediately after completion of the reaction, the azides were 4 
subjected to CuAAC reaction by adding the corresponding alkynes and the Cu(I) in situ forming 5 
reagents. Once the β-ketotriazoles were formed, R. mucilaginosa LSL lyophilized cells were added 6 
and incubated under non-sterile conditions giving the complete and stereoselective reduction of the 7 
bulky-bulky substrates after 24 h (Figure 3). Notably, the copper species present in the reaction 8 
medium did not affect the enzymatic machinery responsible of catalyzing the ketones reduction and 9 
the redox cofactor regeneration. Afterwards, only one purification procedure was necessary to yield 10 
the (R)-β-hydroxytriazoles with a slight improvement in the isolated yield (see Table S3, SI). 11 
On the other hand, we tried to develop a one-pot cascade strategy starting from α-chloroketones and 12 
all the chemicals and the lyophilized biocatalyst. In this process, chlorine was substituted by the azide 13 
nucleophile in SN2 reaction and, in competition the α-chloroketones were bioreduced to the 14 
corresponding chlorohydrins. This divergence furnished two different products resulting in a low 15 
conversion to the desired products (data not shown). Alternatively, we envisaged the use of α-16 
bromoketones in aqueous medium at pH 4.5. This reaction condition was selected to avoid the 17 
formation of by-products such as epoxides, as previously reported [26]. Under this condition, bromine 18 
was substituted by the azide nucleophile in SN2 reaction and, in parallel a small amount of the α-19 
bromoketones were bioreduced to the corresponding bromohydrins (R)-3b and (R)-4b. Since bromide 20 
is a better leaving group than chloride, the bromohydrins were also reactive in SN2 reaction and were 21 
transformed to the β-hydroxyazides. The formation of all these intermediates was confirmed by TLC 22 
and GC-FID (data not shown). Consequently, these products converged efficiently to the synthesis of 23 
the (R)-β-hydroxytriazoles 7b-10b (Figure 4) in up to 80% isolated yield (see Table S3, SI). This 24 
increase in the yield could be attributable to i) the immediate consumption of the unstable azide 25 
compounds as soon as they are formed, ii) the complete substitution of the bromine by the azide even 26 
in the bromohydrin intermediate, iii) the ability of R. mucilaginosa LSL to reduce the bromoketones, 27 
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the azidoketones as well as the bulky-bulky β-ketotriazoles, and iv) the avoidance of intermediates 1 
isolation steps.  2 
 3 
3. Conclusions 4 
The capability of R. mucilaginosa LSL to stereoselectively reduce small-bulky and bulky-bulky 5 
ketones was demonstrated. This biocatalyst can operate as resting and lyophilized cells without the 6 
addition of external cofactors resulting in a valuable tool for green chemistry endeavors. The KRED 7 
responsible of these biotransformations are promising to be further investigated. Based on these facts, 8 
we designed efficient one-pot chemoenzymatic strategies to synthesize (R)-β-hydroxytriazoles. The 9 
carbonyl reductase activity of the yeast was not impaired despite all the chemicals present in the 10 
reaction medium. By a one-pot divergent-convergent process with the appropriate substrate, we could 11 
obtain the desired products in high isolated yields in a very simple, green, cost-effective and easy-to-12 
handle fashion.   13 
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